Home > Result Summaries: Compounds > SB217744 Result Summaries: SB217744 GSKStudy ID Phase Title Summary (Download) 101518 Phase 4 A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) given as a booster at 18-24 months of age to children who have received a three-dose primary immunisation course with the same vaccine in a previous study (1 citation(s))
